STOCK TITAN

[SCHEDULE 13G/A] Janux Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Janus Henderson Group plc reports a passive institutional stake in Janux Therapeutics, Inc. common stock. The filing lists an aggregate beneficial ownership of 4,460,332 shares (7.5% of the class) attributed to the reporting person, while Item 4 separately identifies JHIUS as the beneficial owner of 4,379,232 shares (7.4%). The report shows shared voting and dispositive power over the shares and classifies the reporting person with reporting types IA and HC.

The filing states the shares are held in the ordinary course of business and not with the purpose of changing or influencing issuer control, and discloses that JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries acting as registered investment advisers to managed portfolios.

Janus Henderson Group plc segnala una partecipazione istituzionale passiva nelle azioni ordinarie di Janux Therapeutics, Inc. La comunicazione indica una proprietà beneficiaria aggregata di 4,460,332 azioni (7.5% della classe) attribuita alla persona che presenta la segnalazione, mentre l'Elemento 4 identifica separatamente JHIUS come beneficiario di 4,379,232 azioni (7.4%). Il rapporto mostra il potere di voto e di disposizione condivisi sulle azioni e classifica la persona segnalante con i codici di segnalazione IA e HC.

La dichiarazione precisa che le azioni sono detenute nell'ordinario svolgimento dell'attività e non con lo scopo di modificare o influenzare il controllo dell'emittente, e dichiara che JHIUS, JHIUKL e JHIAIFML sono società controllate indirette che operano come consulenti d'investimento registrati per portafogli gestiti.

Janus Henderson Group plc informa una participación institucional pasiva en acciones ordinarias de Janux Therapeutics, Inc. La presentación indica una titularidad beneficiaria agregada de 4,460,332 acciones (7.5% de la clase) atribuida a la persona informante, mientras que el Punto 4 identifica por separado a JHIUS como beneficiario de 4,379,232 acciones (7.4%). El informe muestra poderes compartidos de voto y de disposición sobre las acciones y clasifica a la persona informante con los tipos de informe IA y HC.

La presentación afirma que las acciones se mantienen en el curso ordinario del negocio y no con el propósito de cambiar o influir en el control del emisor, y revela que JHIUS, JHIUKL y JHIAIFML son filiales indirectas que actúan como asesores de inversión registrados para carteras gestionadas.

Janus Henderson Group plc는 Janux Therapeutics, Inc. 보통주에 대한 수동적 기관 지분을 보고합니다. 제출서류에는 신고인에게 귀속된 총수익적 소유권 4,460,332주(7.5% 해당 클래스)가 기재되어 있으며, 항목 4는 별도로 JHIUS4,379,232주(7.4%)의 수익적 소유자임을 밝힙니다. 보고서는 주식에 대한 공동 의결권 및 처분권을 표시하며 신고인을 신고유형 IAHC로 분류합니다.

제출서류는 해당 주식이 영업의 통상적 범위에서 보유되고 있으며 발행사의 지배권을 변경하거나 영향을 미칠 목적으로 보유된 것이 아님을 명시하고, JHIUS, JHIUKL 및 JHIAIFML이 관리 포트폴리오에 대해 등록된 투자자문사로서 간접 자회사임을 공개합니다.

Janus Henderson Group plc déclare une participation institutionnelle passive dans les actions ordinaires de Janux Therapeutics, Inc. Le dépôt indique une propriété bénéficiaire agrégée de 4,460,332 actions (7.5% de la catégorie) attribuée à la personne déclarante, tandis que l'Item 4 identifie séparément JHIUS comme bénéficiaire de 4,379,232 actions (7.4%). Le rapport montre un pouvoir de vote et de disposition partagé sur les actions et classe la personne déclarante selon les types de déclaration IA et HC.

Le dépôt précise que les actions sont détenues dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contrôle de l'émetteur, et divulgue que JHIUS, JHIUKL et JHIAIFML sont des filiales indirectes agissant comme conseillers en investissement enregistrés pour des portefeuilles gérés.

Janus Henderson Group plc meldet eine passive institutionelle Beteiligung an Stammaktien von Janux Therapeutics, Inc. Die Einreichung weist eine aggregierte wirtschaftliche Eigentümerschaft von 4,460,332 Aktien (7.5% der Klasse) aus, die der meldenden Person zugerechnet wird, während Punkt 4 separat JHIUS als wirtschaftlichen Eigentümer von 4,379,232 Aktien (7.4%) nennt. Der Bericht zeigt gemeinsame Stimm- und Verfügungsmacht über die Aktien und klassifiziert die meldende Person mit den Meldetypen IA und HC.

Die Einreichung stellt fest, dass die Aktien im normalen Geschäftsverlauf gehalten werden und nicht mit dem Ziel, die Kontrolle des Emittenten zu ändern oder zu beeinflussen, und legt offen, dass JHIUS, JHIUKL und JHIAIFML indirekte Tochtergesellschaften sind, die als registrierte Anlageberater für verwaltete Portfolios tätig sind.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: A material passive stake (~7.4-7.5%) by a large asset manager; signals institutional interest but no control intent.

Janus Henderson's position exceeds the 5% threshold, making it a material, reportable holding for Janux (JANX). The filing is a Schedule 13G/A, indicating a passive investment posture; the certification explicitly states the securities "were not acquired for the purpose of changing or influencing control." For investors, institutional ownership at this scale can support liquidity and may reflect confidence from professional managers, but it does not signal strategic influence or an activist campaign. Note the filing lists two close but different share counts in separate sections, which warrants attention for reconciliation.

TL;DR: Ownership is reportable and passive; governance implications are limited absent intent to influence control.

The Schedule 13G/A classification and the signer’s certification indicate a non-control, advisory role for the reporting group. As such, there are no immediate governance or control changes implied by this filing. The disclosure that indirect subsidiaries are registered investment advisers managing portfolios clarifies custodial and voting arrangements. The discrepancy between the aggregate amount (4,460,332) and the Item 4 figure (4,379,232) should be clarified in subsequent filings or exhibits to ensure transparency about exact holdings and voting authority.

Janus Henderson Group plc segnala una partecipazione istituzionale passiva nelle azioni ordinarie di Janux Therapeutics, Inc. La comunicazione indica una proprietà beneficiaria aggregata di 4,460,332 azioni (7.5% della classe) attribuita alla persona che presenta la segnalazione, mentre l'Elemento 4 identifica separatamente JHIUS come beneficiario di 4,379,232 azioni (7.4%). Il rapporto mostra il potere di voto e di disposizione condivisi sulle azioni e classifica la persona segnalante con i codici di segnalazione IA e HC.

La dichiarazione precisa che le azioni sono detenute nell'ordinario svolgimento dell'attività e non con lo scopo di modificare o influenzare il controllo dell'emittente, e dichiara che JHIUS, JHIUKL e JHIAIFML sono società controllate indirette che operano come consulenti d'investimento registrati per portafogli gestiti.

Janus Henderson Group plc informa una participación institucional pasiva en acciones ordinarias de Janux Therapeutics, Inc. La presentación indica una titularidad beneficiaria agregada de 4,460,332 acciones (7.5% de la clase) atribuida a la persona informante, mientras que el Punto 4 identifica por separado a JHIUS como beneficiario de 4,379,232 acciones (7.4%). El informe muestra poderes compartidos de voto y de disposición sobre las acciones y clasifica a la persona informante con los tipos de informe IA y HC.

La presentación afirma que las acciones se mantienen en el curso ordinario del negocio y no con el propósito de cambiar o influir en el control del emisor, y revela que JHIUS, JHIUKL y JHIAIFML son filiales indirectas que actúan como asesores de inversión registrados para carteras gestionadas.

Janus Henderson Group plc는 Janux Therapeutics, Inc. 보통주에 대한 수동적 기관 지분을 보고합니다. 제출서류에는 신고인에게 귀속된 총수익적 소유권 4,460,332주(7.5% 해당 클래스)가 기재되어 있으며, 항목 4는 별도로 JHIUS4,379,232주(7.4%)의 수익적 소유자임을 밝힙니다. 보고서는 주식에 대한 공동 의결권 및 처분권을 표시하며 신고인을 신고유형 IAHC로 분류합니다.

제출서류는 해당 주식이 영업의 통상적 범위에서 보유되고 있으며 발행사의 지배권을 변경하거나 영향을 미칠 목적으로 보유된 것이 아님을 명시하고, JHIUS, JHIUKL 및 JHIAIFML이 관리 포트폴리오에 대해 등록된 투자자문사로서 간접 자회사임을 공개합니다.

Janus Henderson Group plc déclare une participation institutionnelle passive dans les actions ordinaires de Janux Therapeutics, Inc. Le dépôt indique une propriété bénéficiaire agrégée de 4,460,332 actions (7.5% de la catégorie) attribuée à la personne déclarante, tandis que l'Item 4 identifie séparément JHIUS comme bénéficiaire de 4,379,232 actions (7.4%). Le rapport montre un pouvoir de vote et de disposition partagé sur les actions et classe la personne déclarante selon les types de déclaration IA et HC.

Le dépôt précise que les actions sont détenues dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contrôle de l'émetteur, et divulgue que JHIUS, JHIUKL et JHIAIFML sont des filiales indirectes agissant comme conseillers en investissement enregistrés pour des portefeuilles gérés.

Janus Henderson Group plc meldet eine passive institutionelle Beteiligung an Stammaktien von Janux Therapeutics, Inc. Die Einreichung weist eine aggregierte wirtschaftliche Eigentümerschaft von 4,460,332 Aktien (7.5% der Klasse) aus, die der meldenden Person zugerechnet wird, während Punkt 4 separat JHIUS als wirtschaftlichen Eigentümer von 4,379,232 Aktien (7.4%) nennt. Der Bericht zeigt gemeinsame Stimm- und Verfügungsmacht über die Aktien und klassifiziert die meldende Person mit den Meldetypen IA und HC.

Die Einreichung stellt fest, dass die Aktien im normalen Geschäftsverlauf gehalten werden und nicht mit dem Ziel, die Kontrolle des Emittenten zu ändern oder zu beeinflussen, und legt offen, dass JHIUS, JHIUKL und JHIAIFML indirekte Tochtergesellschaften sind, die als registrierte Anlageberater für verwaltete Portfolios tätig sind.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



JANUS HENDERSON GROUP PLC
Signature:Kristin Mariani
Name/Title:Head of North America Compliance, CCO
Date:08/14/2025
Exhibit Information

POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

Janux Therapeutics, Inc.

NASDAQ:JANX

JANX Rankings

JANX Latest News

JANX Latest SEC Filings

JANX Stock Data

1.46B
54.32M
6.69%
113.81%
16.31%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO